{
  "report_rows": [
    {
      "kpi": "BD Biosciences pro forma growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~flat to +1% pro forma vs. cons ~+2.5% implied (UNVERIFIED standalone consensus)",
      "confidence": "LOW"
    },
    {
      "kpi": "Legacy Waters organic growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~7.5-8% vs. cons 6.96% (Visible Alpha, Aug 3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$3.05-$3.10 vs. cons $3.008 (Visible Alpha, Aug 3 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total Revenue - FY 2026 (full year)",
      "prediction": "BETTER",
      "answer": "guide ~$6.50-6.55B vs. cons $6.445B (Visible Alpha, Aug 3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS - FY 2026 (full year)",
      "prediction": "BETTER",
      "answer": "guide ~$14.60-14.70 vs. cons $14.522 (Visible Alpha, Aug 3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS - Q3 2026 (next quarter)",
      "prediction": "BETTER",
      "answer": "guide ~$3.65-3.75 vs. cons ~$3.60 (Visible Alpha, Aug 3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "BD integration tone / qualitative (FY 2026)",
      "prediction": "BETTER",
      "answer": "Biosciences inflects to positive pro forma; synergy phasing confirmed; BACTEC FXI ramp update vs. cons expectation of continued uncertainty",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 8.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sell-side rebuilds H2 estimates on synergy confirmation; all three prior Archetype A quarters showed positive 5-day follow-through (+2.3%, +15.7%, +14.0%); H2 estimate revisions are the mechanism",
  "day5_confidence": "MEDIUM"
}